T1	Participants 62 82	lung cancer patients
T2	Participants 195 233	small cell lung cancer (SCLC) patients
T4	Participants 1425 1466	patients undergoing chemotherapy for SCLC
T3	Participants 330 504	11 patients received either standard (four weekly) chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) or accelerated (two weekly) ICE with filgrastim (granulocyte
